Catalyst Brief

← Calendar

Readoutin 104d

Fujian Shengdi Pharmaceutical Co., Ltd. — HRS9531 injection

Phase 3 primary completion: A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity.

Date
Mar 2027
Type
Readout
Indication
Obesity

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.